Original Articles: PDF OnlyWARFARIN AND OTHER “ANTI”-VITAMIN K ANTICOAGULANTS PHARMACODYNAMICS AND CLINICAL USEFreedman, Michael D.Author Information Johns Hopkins University School of Medicine, and Department of Medicine, Sinai Hospital, Baltimore, MD 21215, USA. Address for correspondence: Department of Internal Medicine, Section of General Internal Medicine, Sinai Hospital of Baltimore, Hoffberger Professional Building, Suite 22, 3435 W. Belvedere Ave., Baltimore, MD 21215, USA. American Journal of Therapeutics: November 1996 - Volume 3 - Issue 11 - p 771-783 Buy Abstract Fortuitously discovered after an episode of bovine hemorrhagic disease, the oral antivitamin K anticoagulants inhibit a posttranslational modification of coagulation factors II, VII, IX, and X that is essential for bioactivity. They also influence formation of regulatory proteins C and S. Although their influence on the extrinsic pathway may be measured using the prothrombin time, a modification thereof produces the International Normalized Ratio (INR) which should allow for less interlaboratory variation. Finding utility in both prophylaxis and treatment of thromboembolic disease, these agents have rendered themselves important pharmacologic tools in the management of deep venous thrombosic, nonvalvular atrial fibrillation, structural heart disease, myocardial infarction, and following major surgical procedures. © Williams & Wilkins 1996. All Rights Reserved.